Jamjoom Pharmaceuticals Factory Past Earnings Performance
Past criteria checks 6/6
Jamjoom Pharmaceuticals Factory has been growing earnings at an average annual rate of 16.8%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 12.4% per year. Jamjoom Pharmaceuticals Factory's return on equity is 24.2%, and it has net margins of 27.6%.
Key information
16.8%
Earnings growth rate
-46.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 12.4% |
| Return on equity | 24.2% |
| Net Margin | 27.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Jamjoom Pharmaceuticals Factory makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,268 | 349 | 373 | 32 |
| 30 Jun 24 | 1,233 | 332 | 383 | 32 |
| 31 Mar 24 | 1,185 | 311 | 368 | 32 |
| 31 Dec 23 | 1,101 | 292 | 352 | 33 |
| 30 Sep 23 | 1,089 | 280 | 351 | 33 |
| 30 Jun 23 | 1,034 | 248 | 341 | 33 |
| 31 Mar 23 | 974 | 212 | 333 | 34 |
| 31 Dec 22 | 917 | 171 | 316 | 33 |
| 30 Sep 22 | 930 | 199 | 312 | 34 |
| 30 Jun 22 | 903 | 212 | 300 | 33 |
| 31 Mar 22 | 822 | 188 | 271 | 35 |
| 31 Dec 21 | 736 | 171 | 252 | 37 |
| 31 Dec 20 | 805 | 207 | 237 | 0 |
| 31 Dec 19 | 732 | 157 | 248 | 0 |
| 31 Dec 18 | 701 | 151 | 271 | 0 |
Quality Earnings: 4015 has high quality earnings.
Growing Profit Margin: 4015's current net profit margins (27.6%) are higher than last year (25.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4015's earnings have grown by 16.8% per year over the past 5 years.
Accelerating Growth: 4015's earnings growth over the past year (24.9%) exceeds its 5-year average (16.8% per year).
Earnings vs Industry: 4015 earnings growth over the past year (24.9%) exceeded the Pharmaceuticals industry 7.3%.
Return on Equity
High ROE: 4015's Return on Equity (24.2%) is considered high.